Shanghai Starry Pharmaceutical Co., Ltd.

Shanghai Sitaili Pharmaceutical Co., Ltd. was established in June 2012 and is a wholly-owned subsidiary of Zhejiang Sitaili Pharmaceutical Co., Ltd. (stock code: 603520), a listed company. Currently, it mainly engages in the research and development and production of non-ionic contrast diagnostic drug formulations. The registered capital of the company is 500 million RMB, covering an area of 75 acres, with a built-up factory of 70000 square meters, and a total asset size exceeding 750 million RMB.

At present, the company has four production lines, namely large volume injection production line, small volume injection production line, cream (hormone) production line and gel production line, and has four varieties and eight specifications of registration approval documents of miconazole nitrate cream, miconazole clobetasol cream, lincomycin lidocaine gel and compound dexamethasone acetate cream.

The company is located in the most critical link of Sitaili Pharmaceutical's "contrast agent full industry chain strategic layout". In 2020, the company's declared products such as iodixanol injection, iodixanol injection, and iodixanol injection were the first to pass the national new Class 4 registration (equivalent to passing the "drug consistency evaluation") and obtained registration approval from the National Medical Products Administration. In 2023, products such as Iomedetomidine Injection (first imitation) and Iovoprofen Injection will be registered as National Class 4 drugs (equivalent to passing the "drug consistency evaluation") and obtain registration approval from the National Medical Products Administration. In 2024, two specifications of Gadebe Glucosamine Injection will receive registration approval from the National Medical Products Administration.

Shanghai Sitaili Pharmaceutical Co., Ltd. has filled the gap in the formulation part of Sitaili Pharmaceutical's industrial chain, enabling the company to successfully complete the industrial transformation and upgrading from raw materials to formulations.